[{"NetIncomeLoss_3_Q3_USD":-122321000.0,"RoyaltyExpense_1_Q3_USD":9000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q3_USD":9000.0,"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0_Q3_USD":21884000.0,"NetCashProvidedByUsedInInvestingActivities_3_Q3_USD":-28270000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q3_USD":0.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0_Q3_USD":608000.0,"AssetsCurrent_0_Q3_USD":162436000.0,"OperatingLeaseExpense_3_Q3_USD":1321000.0,"LongTermDebt_0_Q3_USD":45000000.0,"PaymentsToAcquireAvailableForSaleSecuritiesDebt_3_Q3_USD":49818000.0,"SellingGeneralAndAdministrativeExpense_3_Q3_USD":46943000.0,"SellingGeneralAndAdministrativeExpense_1_Q3_USD":17195000.0,"RoyaltyExpense_3_Q3_USD":78000.0,"FinanceLeaseLiabilityNoncurrent_0_Q3_USD":3919000.0,"CostOfGoodsAndServicesSold_1_Q3_USD":1517000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3_Q3_shares":14154000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q3_shares":16544000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q3_USD":746000.0,"ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_3_Q3_USD":21907000.0,"CommonStockSharesIssued_0_Q3_shares":176566000.0,"InventoryWorkInProcessNetOfReserves_0_Q3_USD":6035000.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q3_USD":49829000.0,"Assets_0_Q3_USD":176226000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q3_USD":6000.0,"ShareBasedCompensation_3_Q3_USD":8907000.0,"LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_0_Q3_USD":20000000.0,"CostOfGoodsAndServicesSold_3_Q3_USD":1517000.0,"PreferredStockParOrStatedValuePerShare_0_Q3_USD":0.001,"AccruedLiabilitiesCurrent_0_Q3_USD":30462000.0,"LineOfCredit_0_Q3_USD":26893000.0,"GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_1_Q3_USD":-12000.0,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q3_USD":403000.0,"ResearchAndDevelopmentExpense_3_Q3_USD":87610000.0,"ResearchAndDevelopmentExpense_1_Q3_USD":30245000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q3_USD":11093000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_3_Q3_shares":164127000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q3_shares":176521000.0,"AccountsReceivableNetCurrent_0_Q3_USD":5422000.0,"CommonStockValue_0_Q3_USD":1766000.0,"AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_0_Q3_USD":3002000.0,"RepaymentsOfLinesOfCredit_3_Q3_USD":5000000.0,"InterestPayableCurrent_0_Q3_USD":19304000.0,"PreferredStockSharesOutstanding_0_Q3_shares":0.0,"ProceedsFromLinesOfCredit_3_Q3_USD":0.0,"NetCashProvidedByUsedInFinancingActivities_3_Q3_USD":103829000.0,"CostsAndExpenses_3_Q3_USD":136148000.0,"CostsAndExpenses_1_Q3_USD":48966000.0,"IncreaseDecreaseInInventories_3_Q3_USD":6241000.0,"ComprehensiveIncomeNetOfTax_3_Q3_USD":-122351000.0,"ComprehensiveIncomeNetOfTax_1_Q3_USD":-46109000.0,"IncreaseDecreaseInAccountsPayable_3_Q3_USD":6725000.0,"OtherAssetsNoncurrent_0_Q3_USD":3646000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q3_USD":96492000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3_Q3_USD":-30000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q3_USD":6000.0,"IncreaseDecreaseInReceivables_3_Q3_USD":-16724000.0,"DepreciationDepletionAndAmortization_3_Q3_USD":568000.0,"GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_3_Q3_USD":31000.0,"ProceedsFromIssuanceOfCommonStock_3_Q3_USD":92848000.0,"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0_Q3_USD":6249000.0,"ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_3_Q3_USD":1000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-92577000.0,"InventoryRawMaterialsNetOfReserves_0_Q3_USD":206000.0,"PaymentsToAcquireProductiveAssets_3_Q3_USD":359000.0,"AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0_Q3_USD":46827000.0,"IncreaseDecreaseInDerivativeAssets_3_Q3_USD":-630000.0,"LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0_Q3_USD":851000.0,"LiabilitiesCurrent_0_Q3_USD":111777000.0,"DeferredRevenueCurrent_0_Q3_USD":432000.0,"AccountsPayableCurrent_0_Q3_USD":11616000.0,"InterestExpense_3_Q3_USD":8892000.0,"InterestExpense_1_Q3_USD":2927000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q3_USD":2873000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q3_USD":5241000.0,"InterestExpenseDebt_3_Q3_USD":8892000.0,"InterestExpenseDebt_1_Q3_USD":2927000.0,"OperatingLeaseWeightedAverageDiscountRatePercent_0_Q3_pure":0.128,"AdditionalPaidInCapital_0_Q3_USD":994811000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q3_USD":98705000.0,"StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1_Q3_USD":366000.0,"LinesOfCreditCurrent_0_Q3_USD":19148000.0,"LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_0_Q3_USD":20000000.0,"PreferredStockSharesIssued_0_Q3_shares":0.0,"ReceivablesNetCurrent_0_Q3_USD":5422000.0,"PropertyPlantAndEquipmentNet_0_Q3_USD":7142000.0,"NetIncomeLoss_1_Q3_USD":-46115000.0,"ProceedsFromStockOptionsExercised_3_Q3_USD":1164000.0,"CommonStockParOrStatedValuePerShare_0_Q3_USD":0.01,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q3_USD":9000.0,"AmortizationOfFinancingCosts_1_Q3_USD":381000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0_Q3_USD":577000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3_Q3_USD":1448000.0,"CommonStockSharesAuthorized_0_Q3_shares":450000000.0,"OperatingIncomeLoss_3_Q3_USD":-122352000.0,"OperatingIncomeLoss_1_Q3_USD":-42864000.0,"NotesPayableCurrent_0_Q3_USD":29890000.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q3_USD":46827000.0,"InventoryNet_0_Q3_USD":6241000.0,"IncreaseDecreaseInInterestPayableNet_3_Q3_USD":4400000.0,"PreferredStockValue_0_Q3_USD":0.0,"LiabilitiesAndStockholdersEquity_0_Q3_USD":176226000.0,"PreferredStockSharesAuthorized_0_Q3_shares":5000000.0,"LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_0_Q3_USD":5000000.0,"AllocatedShareBasedCompensationExpense_3_Q3_USD":8907000.0,"RestrictedCashAndCashEquivalentsAtCarryingValue_0_Q3_USD":2213000.0,"EarningsPerShareBasicAndDiluted_3_Q3_USD":-0.75,"EarningsPerShareBasicAndDiluted_1_Q3_USD":-0.26,"FinanceLeaseLiabilityCurrent_0_Q3_USD":925000.0,"StockholdersEquity_0_Q3_USD":33637000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q3_USD":49789000.0,"RevenueFromContractWithCustomerIncludingAssessedTax_3_Q3_USD":13796000.0,"RevenueFromContractWithCustomerIncludingAssessedTax_1_Q3_USD":6102000.0,"RetainedEarningsAccumulatedDeficit_0_Q3_USD":-962949000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3_Q3_USD":-17018000.0,"CommonStockSharesOutstanding_0_Q3_shares":176566000.0,"AmortizationOfFinancingCosts_3_Q3_USD":1061000.0,"ProceedsFromIssuanceOfWarrants_3_Q3_USD":14817000.0,"IncreaseDecreaseInContractWithCustomerLiability_3_Q3_USD":-1688000.0,"Ticker":"BCRX","CIK":"882796","name":"BIOCRYST PHARMACEUTICALS INC","OfficialName":"BioCryst Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20200930","fy":"2020.0","fp":"Q3","qtrs":"3","uom":"USD","footnote":"nan","Market Cap":"1887243586.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20201106"}]